rBIO announced that it has completed all the required analytical characterizations of its insulin biosimilar, R-biolin. This positions the company to file for the 351(k) drug submission process — an abbreviated licensure pathway for biological products shown to be biosimilar to or interchangeable with an FDA-licensed reference product.
Read MoreGero is a cutting-edge biotechnology company dedicated to the mission of curing age-related human diseases and understanding, slowing, and even halting the aging process itself.
Read MoreGenScript’s new GMP-grade GenExact™ single-stranded DNA (ssDNA) and GenWand™ closed-end linear double-stranded DNA (dsDNA) services enable new workflows
Read MoreAllelica, the leader in Polygenic Risk Scoring, expands scientific advisory board
Read More